Becton, Dickinson and Company BDXB

Full chart Compare
Set alert

Price alert · BDXB

All alert types
48.16 0.00 (+0.00%)

At closeMay 31, 2023, 4:00 PM EDT

47.65 Day range 48.82
45.85 52-week range 52.52
Market cap
13.69B
Revenue (ttm)
18.81B
Profit margin
8.60%
EPS (ttm)
6.33
P/E ratio
7.60
Dividend
3.00 (5.78%)
Ex-dividend date
Aug 11, 2021
Volume
2.76M
Avg volume
449.58K
Open
47.20
Previous close
48.16
Day's range
47.65 – 48.82
52-week range
45.85 – 52.52
Beta
0.56

 

No chart data for this range yet.

Key statistics

Enterprise value
29.92B
PEG ratio
0.00
Price / sales
0.00
Price / book
0.53
Dividend yield
5.78%
Payout ratio
0.00%
Revenue growth
1.50%
Free cash flow
1.76B
Total cash
1.99B
Total debt
18.22B
Return on equity
6.56%
Short % of float
0.00%
50-day average
49.93
200-day average
49.31

Next earnings

Consensus EPS estimate 0.00.

Earnings history

About Becton, Dickinson and Company

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company's BD Medical segment provides peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication and infusion therapy delivery systems, medication compounding workflow systems, automated medication dispensing and supply management systems, and medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes; and prefillable drug delivery systems. Its BD Life Sciences segment offers specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The company's BD Interventional segment provides hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention, surgical and laparoscopic instrumentation products; peripheral intervention products; and urology and critical care products. The company was founded in 1897 and is based in Franklin Lakes, New Jersey.

Sector
Healthcare
Industry
Medical Instruments & Supplies
Country
United States
Website
bd.com

News

No recent headlines

Headlines appear here as they are published.

Your note

Sign in to keep a note on BDXB — it syncs with the Stock Master app.

Institution ownership

BDXB institution ownership
Holder% heldSharesValueReported
Bank Of New York Mellon Corporation0.00%1,159,16855.83MMar 30, 2023
American Century Companies, Inc.0.00%3,997,703192.53MMar 30, 2023
Blackrock Inc.0.00%2,290,001110.29MMar 30, 2023
Camden Asset Management L P /ca0.00%1,308,40063.01MMar 30, 2023
Franklin Resources, Inc.0.00%606,92029.23MMar 30, 2023
Capital World Investors0.00%5,647,202271.97MMar 30, 2023

Fund ownership

BDXB fund ownership
Holder% heldSharesValueReported
Washington Mutual Investors Fund0.00%2,963,696142.73MMar 30, 2023
American Century Equity Income0.00%2,799,928134.84MDec 30, 2022
Income Fund of America Inc0.00%2,467,280118.82MMar 30, 2023
iShares Preferred & Income Securities ETF0.00%2,251,882108.45MFeb 27, 2023
Price (T.Rowe) Equity Income Fund0.00%1,320,00063.57MDec 30, 2022
Franklin Investors Securities Trust-Equity Income Fund0.00%600,00028.90MJan 30, 2023